文献速递糖尿病

阿必鲁肽对比安慰剂治疗成人新诊断1型糖尿病的随机52周2期试验

Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

这项52周随机2期研究纳入新诊断1型糖尿病且仍有残余胰岛素分泌的成人患者,按3:1随机接受每周一次阿必鲁肽30 mg(第6周上调至50 mg)联合胰岛素或安慰剂联合胰岛素。主要终点为混合餐耐受试验刺激后2小时血浆C肽AUC从基线至52周的变化,贝叶斯分析显示两组差异概率低,阿必鲁肽对保留残余β细胞功能无明显影响。

要点

  • 阿必鲁肽30至50 mg每周一次联合胰岛素治疗1年,对新诊断1型糖尿病患者的残余β细胞功能无明显影响。
  • 52周时混合餐耐受试验刺激后2小时血浆C肽AUC变化:安慰剂组-0.16 nmol/L,阿必鲁肽组-0.13 nmol/L。
  • 贝叶斯分析后验治疗差异为0.12 nmol/L(95%可信区间0-0.24),两组差异≥0.2 nmol/L的概率低(0.097)。

核心结论

  • 在新诊断1型糖尿病患者中,每周一次阿必鲁肽30至50 mg治疗1年,对比安慰剂对保留残余β细胞功能无明显影响。

研究设计与样本

  • 52周随机2期研究(NCT02284009),采用预设贝叶斯方法纳入既往研究安慰剂数据,按3:1(阿必鲁肽:安慰剂)随机分组。
  • 研究对象为新诊断1型糖尿病且仍有残余胰岛素分泌的成人患者,干预为每周一次阿必鲁肽30 mg(第6周上调至50 mg)联合胰岛素对比安慰剂联合胰岛素。
  • 主要终点为52周时混合餐耐受试验(MMTT)刺激后2小时血浆C肽曲线下面积(AUC)相对基线的变化。

主要发现

  • 完成研究患者比例:安慰剂组12/17(70.6%),阿必鲁肽组40/50(80.0%)。
  • 本研究中52周时MMTT刺激后2小时血浆C肽AUC相对基线变化:安慰剂组-0.16 nmol/L(标准差0.366),阿必鲁肽组-0.13 nmol/L(标准差0.244)。
  • 主要贝叶斯分析(含既往研究数据)后验治疗差异估计为0.12 nmol/L(95%可信区间0-0.24),两组差异≥0.2 nmol/L的概率低(0.097)。
  • 第28周时最大C肽出现一过性显著差异,其余次要终点未见显著差异。
  • 治疗期间不良事件报告率:阿必鲁肽组82.0%,安慰剂组76.5%。

关键数值与推荐

  • 主要终点为52周时MMTT刺激后2小时血浆C肽AUC相对基线的变化。
  • 阿必鲁肽给药方案为每周一次30 mg,第6周上调至50 mg。
  • 贝叶斯分析后验治疗差异为0.12 nmol/L(95%可信区间0-0.24),两组差异≥0.2 nmol/L的概率为0.097。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: GLP-1 receptor agonists are an established therapy in patients with type 2 diabetes; however, their role in type 1 diabetes remains to be determined. OBJECTIVE: Determine efficacy and safety of once-weekly albiglutide 30 mg (up-titration to 50 mg at week 6) versus placebo together with insulin in patients with new-onset type 1 diabetes and residual insulin production. DESIGN: 52-week, randomized, phase 2 study (NCT02284009). METHODS: A prespecified Bayesian approach, incorporating placebo data from a prior study, allowed for 3:1 (albiglutide:placebo) randomization. The primary endpoint was 52-week change from baseline in mixed meal tolerance test (MMTT) stimulated 2-h plasma C-peptide area under the curve (AUC). Secondary endpoints included metabolic measures and pharmacokinetics of albiglutide. RESULTS: 12/17 (70.6%, placebo) and 40/50 (80.0%, albiglutide) patients completed the study. Within our study, mean (standard deviation) change from baseline to week 52 in MMTT-stimulated 2-h plasma C-peptide AUC was -0.16 nmol/L (0.366) with placebo and -0.13 nmol/L (0.244) with albiglutide. For the primary Bayesian analysis (including prior study data) the posterior treatment difference (95% credible interval) was estimated at 0.12 nmol/L (0-0.24); the probability of a difference ≥0.2 nmol/L between treatments was low (0.097). A transient significant difference in maximum C-peptide was seen at week 28. Otherwise, no significant secondary endpoint differences were noted. On-therapy adverse events were reported in 82.0% (albiglutide) and 76.5% (placebo) of patients. CONCLUSION: In newly diagnosed patients with type 1 diabetes, albiglutide 30 to 50 mg weekly for 1 year had no appreciable effect on preserving residual β-cell function versus placebo.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Pozzilli P, Bosi E, Cirkel D, et al. Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes. J Clin Endocrinol Metab. 2020. PMID: 32219329. doi:10.1210/clinem/dgaa149

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。